| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| ln Vivo |
His-Purkinje conduction time (HV interval) and intraventricular conduction time (QRS duration) are extended by encainide (0.3, 0.9, 2.7 mg/kg; single-dose infusion); however, it has no effect on the recovery time of the sinoatrial node. Or the conduction of the atrioventricular node is unaffected. or ventricular myocardium, atrioventricular node, or refractory or QT interval of the atrium [1].
|
|---|---|
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Radiolabeled encarnib doses are primarily excreted via urine and feces, with roughly equal amounts excreted. Metabolisms/Metabolites Known metabolites of encarnib include O-desmethylencarnib and N-desmethylencarnib. Biological Half-Life 1–2 hours |
| References |
[1]. R N Brogden, et al. Encainide. A review of its pharmacological properties and therapeutic efficacy. Drugs. 1987 Nov;34(5):519-38.
|
| Additional Infomation |
Encainide is a 4-methoxy-N-phenylbenzamide in which the hydrogen at the 2-position of the benzene ring is replaced by a 2-(1-methylpiperidin-2-yl)ethyl group. As a class Ic antiarrhythmic drug, its hydrochloride salt was used to treat serious or life-threatening ventricular arrhythmias, but was withdrawn from the market due to its association with increased mortality in patients with asymptomatic arrhythmias following recent myocardial infarction. It has both antiarrhythmic and sodium channel blocker effects. It belongs to the piperidine and benzamide classes. All pharmaceutical products containing encainide hydrochloride. Encainide hydrochloride (formerly marketed as Enkaid capsules) was associated with increased mortality in patients with asymptomatic arrhythmias following recent myocardial infarction. The manufacturer of encainide capsules voluntarily withdrew the product from the U.S. market on December 16, 1991. Encainide is an antiarrhythmic drug that slows conduction in the His-Purkinje system and myocardium by blocking voltage-gated sodium channels. Drug Indications Encani is a class Ic antiarrhythmic drug used to treat arrhythmias such as atrial fibrillation, atrial flutter, ventricular tachycardia, and ventricular fibrillation. Mechanism of Action Encani is a sodium channel blocker that binds to voltage-gated sodium channels, stabilizing neuronal membranes by inhibiting the ion flow required for impulse initiation and conduction. It reduces diastolic ventricular excitability and increases the ventricular stimulation threshold. Pharmacodynamics Encani is used to treat arrhythmias by slowing conduction in the atria, atrioventricular node, His-Purkinje system, and within the ventricles, thereby reducing ventricular excitability, conduction velocity, and automaticity. It can slightly but significantly prolong the effective refractory period of these tissues. Its effect on the His-Purkinje system is greatest. Encani reduces the rate of action potential rise but has little effect on its duration.
|
| Molecular Formula |
C22H28N2O2
|
|---|---|
| Molecular Weight |
352.478
|
| Exact Mass |
352.215
|
| CAS # |
66778-36-7
|
| Related CAS # |
Encainide hydrochloride;66794-74-9
|
| PubChem CID |
48041
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.375
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
26
|
| Complexity |
434
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN1CCCCC1CCC2=CC=CC=C2NC(=O)C3=CC=C(C=C3)OC
|
| InChi Key |
PJWPNDMDCLXCOM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H28N2O2/c1-24-16-6-5-8-19(24)13-10-17-7-3-4-9-21(17)23-22(25)18-11-14-20(26-2)15-12-18/h3-4,7,9,11-12,14-15,19H,5-6,8,10,13,16H2,1-2H3,(H,23,25)
|
| Chemical Name |
4-methoxy-N-[2-[2-(1-methylpiperidin-2-yl)ethyl]phenyl]benzamide
|
| Synonyms |
MJ 9067; Encainide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8370 mL | 14.1852 mL | 28.3704 mL | |
| 5 mM | 0.5674 mL | 2.8370 mL | 5.6741 mL | |
| 10 mM | 0.2837 mL | 1.4185 mL | 2.8370 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
